ES2665917T3 - Endoxifeno para su uso en el tratamiento del cáncer - Google Patents

Endoxifeno para su uso en el tratamiento del cáncer Download PDF

Info

Publication number
ES2665917T3
ES2665917T3 ES07871563.8T ES07871563T ES2665917T3 ES 2665917 T3 ES2665917 T3 ES 2665917T3 ES 07871563 T ES07871563 T ES 07871563T ES 2665917 T3 ES2665917 T3 ES 2665917T3
Authority
ES
Spain
Prior art keywords
endoxifene
cancer treatment
endoxyphene
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07871563.8T
Other languages
English (en)
Spanish (es)
Inventor
Ateeq Ahmad
Shoukath M. Ali
Moghis U. Ahmad
Saifuddin Sheikh
Imran Ahmad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jina Pharmaceuticals Inc
Original Assignee
Jina Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39492975&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2665917(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jina Pharmaceuticals Inc filed Critical Jina Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2665917T3 publication Critical patent/ES2665917T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
ES07871563.8T 2006-11-21 2007-11-21 Endoxifeno para su uso en el tratamiento del cáncer Active ES2665917T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86042006P 2006-11-21 2006-11-21
US860420P 2006-11-21
US86078806P 2006-11-22 2006-11-22
US860788P 2006-11-22
PCT/US2007/085443 WO2008070463A2 (en) 2006-11-21 2007-11-21 Endoxifen methods and compositions

Publications (1)

Publication Number Publication Date
ES2665917T3 true ES2665917T3 (es) 2018-04-30

Family

ID=39492975

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07871563.8T Active ES2665917T3 (es) 2006-11-21 2007-11-21 Endoxifeno para su uso en el tratamiento del cáncer

Country Status (11)

Country Link
US (2) US9333190B2 (cg-RX-API-DMAC7.html)
EP (1) EP2101731B1 (cg-RX-API-DMAC7.html)
JP (1) JP2010510327A (cg-RX-API-DMAC7.html)
CA (1) CA2669913C (cg-RX-API-DMAC7.html)
DK (1) DK2101731T3 (cg-RX-API-DMAC7.html)
ES (1) ES2665917T3 (cg-RX-API-DMAC7.html)
HU (1) HUE037109T2 (cg-RX-API-DMAC7.html)
IN (1) IN2014MN00139A (cg-RX-API-DMAC7.html)
PL (1) PL2101731T3 (cg-RX-API-DMAC7.html)
PT (1) PT2101731T (cg-RX-API-DMAC7.html)
WO (1) WO2008070463A2 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2101731T3 (en) 2006-11-21 2018-04-16 Jina Pharmaceuticals Inc ENDOXIFEN FOR USING CANCER TREATMENT
US20090291134A1 (en) 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
EP3656376A1 (en) * 2008-12-11 2020-05-27 Besins Healthcare Luxembourg SARL Transdermal pharmaceutical compositions comprising a serm
RS63747B1 (sr) 2011-04-28 2022-12-30 Oncopeptides Ab Liofilizovani preparat citotoksičnih dipeptida
EP2668945A1 (de) 2012-06-01 2013-12-04 Bayer Technology Services GmbH Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
EP2928463B1 (en) * 2012-10-26 2019-11-20 Oncopeptides AB Lyophilized preparations of melphalan flufenamide
CN108024959A (zh) * 2015-07-14 2018-05-11 阿托萨遗传学公司 用于治疗乳腺病症的经乳头方法和组合物
DE102015222031A1 (de) 2015-11-10 2017-05-11 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Synthese von (Z)-Endoxifenhydrochlorid
US20170304232A1 (en) * 2016-04-20 2017-10-26 Northwestern University Endoxifen For Local Transdermal Therapy To The Breast
TWI878810B (zh) 2017-09-11 2025-04-01 美商阿托薩醫療公司 製造及使用因多昔芬(endoxifen)之方法
CA3074302A1 (en) * 2017-09-11 2019-03-14 Atossa Therapeutics, Inc. Topical compositions and methods for treatment
CA3145867A1 (en) 2019-07-03 2021-01-07 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
CA3177260A1 (en) 2020-04-10 2021-10-14 Jina Pharmaceuticals, Inc. Endoxifen for the treatment of bipolar i disorder
EP4132498A4 (en) 2020-04-10 2024-04-17 Jina Pharmaceuticals Inc. Endoxifen for the treatment of bipolar i disorder
TW202302073A (zh) * 2021-03-18 2023-01-16 予宇生技股份有限公司 包含帶電脂質的脂質製劑的組合物及製備方法
US20250066286A1 (en) 2022-01-12 2025-02-27 Atossa Therapeutics, Inc. Compositions of (z)-endoxifen and methods of enrichment thereof
CA3250298A1 (en) * 2022-04-26 2023-11-02 Atossa Therapeutics, Inc. High dose endoxifen formulations and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2817157A1 (de) * 1978-04-17 1979-10-25 Schering Ag Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie
JPH10503769A (ja) * 1994-08-04 1998-04-07 クアドラント ホールディングス ケンブリッジ リミテッド 配合されている分子の制御放出用の固形放出系およびその製造方法
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
JP2001507207A (ja) * 1996-05-01 2001-06-05 イマアーレクス・フアーマシユーチカル・コーポレーシヨン 化合物を細胞に送達する方法
US6090407A (en) * 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
EP2076244B1 (en) 2006-10-10 2016-12-07 Jina Pharmaceuticals Inc. Aqueous systems for the preparation of lipid-based pharmaceutical compounds; compositions, methods, and uses thereof
WO2008048194A1 (en) 2006-10-20 2008-04-24 Yesilogluj Aysegul Yildiz Use of the protein kinase c inhibitor tamoxifen for the treatment of bipolar disorder
CA2669355C (en) 2006-11-06 2012-10-30 Jina Pharmaceuticals, Inc. Guggulphospholipid methods and compositions
DK2101731T3 (en) 2006-11-21 2018-04-16 Jina Pharmaceuticals Inc ENDOXIFEN FOR USING CANCER TREATMENT
US20090291134A1 (en) 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
JP5720881B2 (ja) 2011-01-31 2015-05-20 東芝ライテック株式会社 Ｌｅｄランプ点灯装置および照明装置

Also Published As

Publication number Publication date
HUE037109T2 (hu) 2018-08-28
EP2101731A2 (en) 2009-09-23
US20160346230A1 (en) 2016-12-01
US10376479B2 (en) 2019-08-13
CA2669913C (en) 2012-09-18
JP2010510327A (ja) 2010-04-02
CA2669913A1 (en) 2008-06-12
WO2008070463A3 (en) 2008-11-06
WO2008070463A2 (en) 2008-06-12
EP2101731B1 (en) 2018-01-31
US9333190B2 (en) 2016-05-10
DK2101731T3 (en) 2018-04-16
IN2014MN00139A (cg-RX-API-DMAC7.html) 2015-06-19
WO2008070463A9 (en) 2008-09-18
PT2101731T (pt) 2018-04-18
US20100112041A1 (en) 2010-05-06
PL2101731T3 (pl) 2018-07-31
EP2101731A4 (en) 2011-04-20

Similar Documents

Publication Publication Date Title
ES2665917T3 (es) Endoxifeno para su uso en el tratamiento del cáncer
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
ES2629749T3 (es) Inmunidad tumoral
ES2496092T3 (es) El uso de amisulprida para tratar náuseas y vómitos posoperatorios
ES2575152T3 (es) Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
ES2649340T3 (es) Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
ES2483725T3 (es) Composición básica cosmética y su uso
CL2008001656A1 (es) Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene.
ES2602810T3 (es) Composición mejorada
ES2478820T3 (es) Tratamiento de degeneración macular
CL2008002369A1 (es) Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer.
CL2009000545A1 (es) Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer.
ES2515168T3 (es) Detección y tratamiento de la esquizofrenia
CL2007003138A1 (es) Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2008001024A1 (es) Compuestos derivados de ftalazinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades cardiovasculares, parkinson, enfermedades inflamatorias, esclerosis multiple, cancer, entre otras
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
ES2563777T3 (es) Compuestos de nitrona para tratar la pérdida auditiva sensorineural
ES2546198T3 (es) Tratamiento contra la glomerulonefritis
ES2496669T3 (es) Agentes antitumorales con una estructura de benzofenantridina y formulaciones que los contienen
ES2531516T3 (es) Uso de escina
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
CR11859A (es) Composición y proceso-356
CO6321285A2 (es) Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria
ES2505643T3 (es) Galectina para uso en el tratamiento del síndrome del ojo seco
ES2629309T3 (es) Formulaciones de tratamiento de la mucositis inducida por terapia antitumoral o inmunosupresora